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ARTICLE
Galectin-9 binds IgM-BCR to regulate B cell
signaling
Anh Cao 1, Nouf Alluqmani2, Fatima Hifza Mohammed Buhari3, Laabiah Wasim1, Logan K. Smith1,
Andrew T. Quaile 4, Michael Shannon5, Zaki Hakim2, Hossai Furmli3, Dylan M. Owen5, Alexei Savchenko4,6 &
Bebhinn Treanor 1,2,3
The galectin family of secreted lectins have emerged as important regulators of immune
cell function; however, their role in B-cell responses is poorly understood. Here we identify
IgM-BCR as a ligand for galectin-9. Furthermore, we show enhanced BCR microcluster
formation and signaling in galectin-9-deficient B cells. Notably, treatment with exogenous
recombinant galectin-9 nearly completely abolishes BCR signaling. We investigated the
molecular mechanism for galectin-9-mediated inhibition of BCR signaling using super-
resolution imaging and single-particle tracking. We show that galectin-9 merges pre-existing
nanoclusters of IgM-BCR, immobilizes IgM-BCR, and relocalizes IgM-BCR together with
the inhibitory molecules CD45 and CD22. In resting naive cells, we use dual-color super-
resolution imaging to demonstrate that galectin-9 mediates the close association of IgM
and CD22, and propose that the loss of this association provides a mechanism for enhanced
activation of galectin-9-deficient B cells.
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B cells play a critical role in the immune response andproduction of protective antibodies. B-cell activation istriggered by binding of antigen to the B-cell receptor
(BCR), which initiates a cascade of intracellular signaling through
assembly of a multiprotein complex of kinases and adaptors1.
B-cell activation is accompanied by formation of numerous
signaling microclusters2. Similar microstructures of antigen
receptors have been described in T cells3 and thus have been
proposed to represent the basic unit of lymphocyte signaling4.
These observations implicate receptor clustering as a mechanism
to regulate signaling events, and consequently the cellular out-
come of receptor engagement. Indeed, the size and spatial pat-
terning of signaling assemblies significantly contribute to cellular
outcomes, with even small variations resulting in altered
responses5–7.
Two key parameters influencing the assembly of signaling
clusters and regulation of membrane receptor activation are the
constitutive nanoscale clustering of membrane proteins referred
to as nanoclusters or protein islands8–10, and the cell surface
mobility of membrane proteins (or nanoclusters of proteins)
7,11,12. These parameters have important implications for receptor
triggering and the assembly of signaling complexes as they
influence the interaction between protein partners. Several
mechanisms have been identified that impact on the organization
and mobility of membrane proteins, including the actin cytos-
keleton11–13, protein–protein interactions9,14–16, and membrane
microdomains defined by lipid composition8,17.
An often overlooked mechanism controlling membrane pro-
tein organization and mobility is the interaction of these cell
surface glycoproteins with the family of soluble secreted lectins,
known as galectins, which bind and crosslink cell surface pro-
teins, generating glycan-based domains18. Indeed, the galectin
lattice influences glycoprotein compartmentalization and lateral
mobility at the cell surface19–21. These proteins have emerged as
important regulators of the immune response. For example,
T cells from mice deficient in Mgat5, which encodes a glycosyl-
transferase involved in generation of galectin-binding epitopes,
have enhanced T-cell receptor (TCR) clustering at the immuno-
logical synapse and increased TCR signaling22. In comparison to
T cells, relatively little is known about glycan–galectin interac-
tions in B cells; however, pre-BCR clustering at the pre-B-cell-
stromal cell synapse is dependent on pre-BCR/galectin-1/integrin
interactions23. Interestingly, a recent study demonstrated
decreased antibody titers upon immunization in mice treated
with recombinant galectin-924. Galectin-9 belongs to the tandem-
repeat subfamily of galectins, which contain two different car-
bohydrate recognition domains (CRDs) separated by a flexible
linker25. In T cells, galectin-9 induces cell death of T helper type 1
(TH1) cells through binding to Tim-326, as well as suppresses
generation of TH17 cells and promotes induction of Tregs27.
However, the role of galectin-9 in B cells, and the molecular
mechanism for decreased antibody production in galectin-9-
treated mice has not been investigated.
Here we identify IgM-BCR and CD45 as ligands for galectin-9.
Further, we show enhanced BCR microcluster formation and
signaling in galectin-9-deficient B cells. Notably, treatment with
exogenous recombinant galectin-9 (rGal9) nearly completely
abolishes BCR signaling. We investigated the molecular
mechanism for galectin-9-mediated inhibition of BCR signaling.
We show using super-resolution imaging and single-particle
tracking that galectin-9 brings together pre-formed BCR
nanoclusters and reduces BCR mobility at the cell surface, and
consequently attenuates BCR microcluster formation. We further
interrogated the effect of galectin-9 on the organization of cell
surface proteins and demonstrate that galectin-9 increases the
molecular density of IgM, CD45, CD22, and CD19 within this
galectin lattice. Using dual-color direct stochastic optical recon-
struction microscopy (dSTORM), we show that galectin-9 med-
iates close association of IgM and CD22 in resting naive B cells
and thus propose a novel role for galectin-9 in regulation of B-cell
activation.
Results
Galectin-9 is bound to the surface of primary naive B cells. To
investigate the underlying mechanism for decreased antibody
production in galectin-9-treated mice24, we initially asked if
galectin-9 is bound to the surface of B cells. Primary naive B cells
were isolated from C57BL/6 (wild type; WT) and Lgals9−/−
(Gal9-KO) mice, stained with a fluorescently labeled antibody
specific for galectin-9 and examined by flow cytometry and
confocal microscopy. We found that galectin-9 is bound to the
surface of WT B cells (Fig. 1a), organized in discrete puncta
(Fig. 1b). To investigate the in vivo expression of galectin-9, we
immunostained inguinal lymph nodes to identify subcapsular
sinus macrophages (CD169), B cells (B220), and galectin-9. We
found that galectin-9 was readily detectable within the B-cell
follicle (Fig. 1c).
Galectin-9 regulates BCR microclusters and signaling. To
investigate the effect of galectin-9 deficiency on BCR microcluster
formation we employed artificial planar lipid bilayers in which
fluorescently labeled anti-BCR antibodies as surrogate antigen are
tethered to mimic the in vivo environment of antigen encoun-
ter28. Naive B cells from WT and Gal9-KO mice were settled on
lipid bilayers containing anti-kappa, fixed after 90 s, and visua-
lized by confocal microscopy. WT B cells spread and form
multiple BCR-antigen microclusters2,29 (Fig. 2a). Gal9-KO B cells
also spread and form microclusters; however, the area of cell-
bilayer contact, and total intensity of antigen is increased
(Fig. 2a–c). Moreover, the mean antigen intensity is also increased
in Gal9-KO B cells, indicating that the amount of BCR-antigen
within individual clusters is increased (Fig. 2d). Given this
enhanced microcluster formation, we asked if BCR signaling was
altered in Gal9-deficient B cells. Consistent with microcluster
data, total tyrosine phosphorylation was increased in Gal9-KO B
cells (Fig. 2e). To further investigate this enhanced signaling, we
examined phosphorylation of downstream signaling molecules,
including CD19, Akt, and extracellular regulated kinase
(ERK1/2). Although we did not detect any increase in phospho-
CD19 or phospho-Akt, we found that phosphorylation of ERK1/2
was increased in Gal9-KO B cells (Fig. 2f–h). We verified that
these differences were not due to altered expression of BCR or
CD19 (Supplementary Fig. 1). These data demonstrate that
galectin-9 regulates BCR microcluster formation and signaling.
To determine if enhanced microcluster formation and signal-
ing is specifically due to loss of galectin-9 at the cell surface, we
titrated the amount of recombinant galectin-9 (rGal9) added to
Gal9-KO B cells from 0.1 to 1 μM and then stained cells with
anti-galectin-9 antibody and compared this to untreated
WT cells. We found that 0.1 μM rGal9 added to Gal9-KO cells
was roughly equivalent to the level of endogenous galectin-9 on
WT cells (Fig. 3a). We treated Gal9-KO B cells with 0.1 µM rGal9
and then stimulated with anti-IgM and examined ERK phos-
phorylation as we found this pathway was enhanced in galectin-
9-deficient cells. We found that this treatment was sufficient to
restore BCR signaling to that observed in WT B cells (Fig. 3b),
demonstrating that the effect of deficiency of galectin-9 is indeed
due to lack of galectin-9 at the cell surface. Given that galectin
family members share the basic glycan ligand, N-acetyllactosa-
mine, we examined an alternative galectin-deficient mouse model.
In contrast to Gal9-KO B cells, we found no difference in BCR
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microcluster formation or downstream signaling in galectin-1-
deficient B cells (Supplementary Fig. 2). These data, while not
exhaustive of the galectin family, provide strong evidence for
specificity of galectin-9 in regulation of these early events of B-cell
activation, consistent with studies demonstrating that structural
differences in the carbohydrate recognition domain (CRD) of
galectin-1 and galectin-9 define specific interactions with cell
surface glycoproteins30.
We noted that ligands for galectin-9 at the cell surface were not
saturated in primary naive B cells and we could add 10-fold more
rGal9 to both WT and Gal9-KO B cells (Fig. 3a). Thus, we asked
what happens to BCR signaling if we increase the amount of
galectin-9 bound to the surface. We observed a substantial
reduction in total tyrosine phosphorylation, as well as phosphor-
ylation of CD19, Akt, and ERK upon pre-treatment of WT cells
with rGal9 (Fig. 3c–f). These differences were not due to altered
expression of BCR, CD19, or CD45 by rGal9 (Supplementary
Fig. 3), nor galectin-9-induced cell death (Supplementary Fig. 4),
as has been reported for thymocytes and T cells26,31,32.
Galectin-9 binds IgM-BCR and CD45. Our data demonstrate an
important role for galectin-9 in regulating BCR signaling; how-
ever, the cell surface glycoproteins that bind galectin-9 in B cells
have not been identified. To identify potential ligands we
performed a pull-down assay using rGal9 followed by mass
spectrometry33. To not compete with endogenous galectin-9,
Gal9-KO primary B cells were lysed, incubated with FLAG-tagged
rGal9 followed by magnetic separation using beads conjugated
with anti-FLAG, and the ligands were eluted using lactose
(Fig. 4a). Isolated proteins were subjected to in-solution tryptic
digestion and liquid chromatography tandem mass spectrometry.
We identified several potential ligands of galectin-9 in B cells,
including CD45 (Ptprc), IgM-BCR (Ighm), and the BCR-
associated signaling chain CD79b (Igβ) (Table 1). To confirm
the identity of these ligands, we performed a pull-down assay
using rGal9 under stringent cell lysis conditions to disrupt
protein–protein interactions followed by western blotting
(Fig. 4b). Consistent with our mass spectrometry results, we
identified CD45 and IgM-BCR as potential ligands of galectin-9.
To verify that these were indeed direct ligands of galectin-9, we
performed far-western analysis34 using FLAG-tagged rGal9 as
bait protein. We detected galectin-9-binding proteins corre-
sponding to the size of CD45 and IgM in reference blots (Fig. 4c)
in primary murine B cells. Importantly, a band corresponding to
the size of IgM was not detected in far-western using cell lysates
from the A20 B-cell line that does not express endogenous IgM.
Conversely, a band corresponding to the size of IgM was detected
in lysates of A20 B cells expressing hen egg lysozyme (Hel)-
specific IgM (D1.3). Neither CD45 (B220) nor IgM bands were
detected when Jurkat T cells were used. These data provide strong
evidence that galectin-9 binds IgM-BCR and CD45.
Galectin-9 alters IgM-BCR nanoclusters. Identification of IgM-
BCR as a ligand of galectin-9, and the potential of galectins to act
as cell surface scaffolding proteins19 led us to ask whether
galectin-9 has a role in organizing IgM-BCR nanoclusters. To
investigate this, we employed dSTORM35, which permits a lateral
resolution of approximately 20 nm, and has been used to
study the organization of IgM, IgD, and IgG BCRs9,10,36.
Primary WT and Gal9-KO B cells were labeled with Alexa
Fluor 647-conjugated anti-IgM Fab fragment, settled on
non-BCR-stimulating anti-major histocompatibility complex
(MHC) II-coated coverslips to adhere cells, then fixed and imaged
by total internal reflection fluorescence microscopy (TIRFM).
IgM-BCR are organized into nanoscale clusters in WT B cells9
(Fig. 5a). Nanoclusters of IgM-BCR were also clearly visible in
dSTORM images in Gal9-KO B cells, with no obvious difference
compared to WT B cells (Fig. 5a). To quantify clustering tendency
of IgM-BCR, we used two methods commonly used to assess
distribution of proteins from super-resolution images37. The
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Fig. 1 Galectin-9 is bound to the surface of primary naive B cells. a Representative flow cytometry plot (left) and quantification (right) of geometric mean ±
SEM of surface staining for galectin-9 in WT (black) and Gal9-KO (blue) B cells from nine independent experiments. b Representative DIC (left) and
confocal microscopy images (right) mapped to an 8-bit fire color scale (ImageJ) of primary WT (top) and Gal9-KO B cells (bottom) stained for surface
galectin-9. Quantification of number of galectin-9 puncta is shown on the right (each dot represents 1 cell, 20 cells measured per condition) with the mean
± SEM indicated by the red bar. Scale bar 2 μm. Data representative of three independent experiments. c Representative confocal microscopy images of
cryosections of the inguinal lymph node of WT B cells stained for subcapsular sinus macrophages (CD169; blue), B cells (B220; magenta), and Gal9
(green). Scale bar 20 μm. Data representative of three independent experiments. Statistical significance was assessed by Mann-Whitney, ****p < 0.0001
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Hopkins index, which evaluates clustering tendency compared to
a random distribution (value of 0.5), was 0.75 for IgM-BCR on
both WT and Gal9-KO B cells (Fig. 5b). The H function derived
from Ripley’s K function evaluates the extent of clustering; dis-
tance of the H function peak is related to cluster radius and peak
height depends on density of molecules in clusters. We found no
difference in the H function curve in Gal9-KO B cells compared
to WT B cells. These findings suggest that galectin-9 does not
mediate formation of IgM-BCR nanoclusters; however, galectin-9
is sparsely distributed at the cell surface of naive B cells (Fig. 1b),
and therefore dSTORM analysis based on randomly selected
regions may underestimate an effect specifically within the
galectin-9 lattice. To focus our dSTORM analysis on the galectin-
9 lattice, we treated Gal9-KO B cells with fluorescently labeled
rGal9. We found that this treatment altered the organization of
IgM-BCR, which appeared more clustered compared to WT and
Gal9-KO cells (Fig. 5a). Both the Hopkin’s index and the H
function of Ripley’s K derived from regions where galectin-9
localized indicated that IgM-BCR was more highly clustered
(Fig. 5b, c). The radius of clusters of IgM-BCR inside the galectin-
9 lattice is approximately 150–250 nm, compared to 50–100 nm
in WT and Gal9-KO B cells (Fig. 5c). To further quantify the
effect of galectin-9 on organization of IgM, we used Bayesian
cluster analysis38. This method is advantageous because: (1) it
accounts for non-negligible unclustered background, which can
interfere with Ripley’s and Hopkins analysis; (2) it takes account
of the uncertainty associated with each localization assigned by
the Gaussian function; and (3) it reduces the bias arising
from subjective user-defined analysis parameters, such as
threshold and cluster radius. Using this method, we identified
the number of clusters per region, cluster radii, number of
molecules per cluster, and percentage of localizations in
clusters from 3 × 3 μm regions of interest from reconstructed
images. Treatment with rGal9 decreased the number of clusters
(Fig. 5d), whereas radius of clusters (Fig. 5e) and number of
molecules per cluster (Fig. 5f) increased. There was no difference
in percentage of localizations within clusters between WT, Gal9-
KO, and Gal9-KO treated with rGal9 (Fig. 5g). These findings
suggest that galectin-9 brings pre-existing IgM-BCR nanoclusters
together, increasing size of clusters and number of molecules
per cluster, but without affecting percentage of molecules residing
in clusters.
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Fig. 2 Galectin-9 regulates BCR microcluster formation and signaling. a Representative images of primary naive WT (top) and Gal9-KO B cells (bottom)
fixed on bilayers containing anti-kappa as surrogate antigen (Ag) after 90 s of spreading and imaged by confocal microscopy. Brightfield (left) and confocal
(right) visualizing antigen mapped to an 8-bit fire color scale (ImageJ). Scale bar 2 μm. Quantification of b area of spreading, c total antigen fluorescence
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200 cells measured per condition), with the mean ± SEM indicated by the red bar, ****p < 0.0001, Mann-Whitney test. Data representative of at least three
independent experiments. e–h Primary naive B cells from WT and Gal9-KO mice were settled onto anti-IgM-coated plates for the indicated time. Cells
were lysed and subjected to SDS-PAGE followed by immunoblotting with e anti-phosphotyrosine and anti-ERK1/2, f anti-phospho-CD19, g anti-phospho-
Akt, and h anti-phospho ERK1/2 (pERK) and anti-β tubulin. Data representative of at least three independent experiments. f Quantification of the fold
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Galectin-9 immobilizes IgM-BCR. The mobility of IgM-BCR is a
critical factor regulating BCR signaling9,12. Given dSTORM
analysis showed galectin-9 increased cluster size, we wondered
whether altered BCR mobility may account for suppressed BCR
signaling upon treatment with rGal9. To investigate the effect of
galectin-9 on IgM mobility in the steady state, we labeled single
particles of IgM on WT and Gal9-KO B cells with Atto-633-
conjugated anti-IgM Fab fragments. Cells were settled on anti-
MHC II-coated coverslips and single molecules of IgM were
visualized using TIRFM. The median diffusion coefficient of IgM-
BCR on Gal9-KO B cells was approximately 30% higher than that
on WT B cells (0.037 μm2/s compared to 0.027 μm2/s; Fig. 6a),
consistent with a decrease in the relative frequency of slow-
moving IgM-BCR in Gal9-KO B cells (Fig. 6b). To examine the
mobility of IgM-BCR inside the galectin-9 lattice, we treated
Gal9-KO B cells with fluorescently labeled rGal9 and visualized
and tracked IgM-BCR. We defined regions of high and low
galectin-9 using the fluorescence intensity of galectin-9 and then
calculated diffusion coefficient in these regions (Fig. 6c). The
median diffusion coefficient of IgM in galectin-9-high regions was
reduced twofold compared to galectin-9-low regions (0.012 μm2/s
compared to 0.028 μm2/s) (Fig. 6d). Approximately 65% of
tracked IgM molecules are largely immobilized inside the mask
compared to 45% of tracked IgM molecules outside the mask
(Fig. 6e). This finding provides direct evidence for galectin-9 to
restrict the mobility of IgM molecules on the B-cell membrane.
We hypothesized that galectin-9-mediated immobilization of
IgM-BCR would reduce BCR localization to the contact with an
antigen-containing membrane. To test this, we settled WT B cells
or cells pre-treated with rGal9 on planar lipid bilayers containing
anti-kappa as surrogate antigen for 90 s and then fixed and
visualized by confocal microscopy. We found that BCR-antigen
aggregation is reduced in cells treated with rGal9 (Fig. 6f, g).
These findings suggest that galectin-9 binds IgM-BCR inducing
aggregation and immobilization of IgM nanoclusters, which
consequently affects the formation of signaling microclusters
upon BCR stimulation.
Galectin-9 increases the density of IgM-BCR and co-receptors.
Our finding that rGal9 induces an increase in the size of IgM-
BCR clusters and immobilization of IgM are also features con-
sistent with the activation of B cells9,10,15,39. To examine if
galectin-9 mediated clustering of IgM was sufficient to induce
signaling, we examined calcium flux upon treatment of cells with
rGal9 by flow cytometry. In contrast to stimulation with anti-
BCR antibodies, we did not detect any increase in intracellular
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calcium upon addition of rGal9 (Supplementary Fig. 5). This
finding raises the question of why treatment with rGal9, which
clusters BCR, does not itself induce B-cell activation. Our data
also identified CD45, the most abundant phosphatase on the B-
cell surface, as a ligand of galectin-9 (Fig. 4). CD45 is a member of
the protein tyrosine phosphatase family and plays an important
role in both positive and negative regulation of B-cell activation
through dephosphorylation of the activating and inhibitory sites
of the Src family kinase Lyn40. This dual regulation of BCR sig-
naling by CD45 is dependent on the localization of CD45, as
CD45 constitutively dephosphorylates and inactivates Lyn within
glycosphingolipid-enriched domains (GEMs), and BCR ligation
induces sequestration of CD45 from GEMs41. We predicted that
galectin-9 modifies the spatial organization of IgM and CD45 to
attenuate signaling. To visualize the effect of galectin-9 on orga-
nization of CD45 relative to IgM-BCR, we treated primary WT B
cells with 1 μM rGal9 and then fixed and immunostained using
anti-CD45, anti-IgM, and anti-galectin-9 antibodies, and imaged
by confocal microscopy. Interestingly, rGal9 often forms a cap at
one side of the cell, consistent with the ability of galectins to form
a lattice-like structure through galectin–glycoprotein interactions
(Fig. 7a). We also observed that within the galectin-9 cap, the
fluorescence intensity of CD45 and IgM is increased (Fig. 7a, b).
To quantify this observation, we developed a protocol to define
galectin-9-high regions (Gal9high) and galectin-9-low regions
(Gal9low) (Fig. 7c) and found that the mean fluorescence intensity
of both CD45 and IgM is significantly higher in Gal9high regions
compared to Gal9low regions (Fig. 7d).
Reorganization of IgM and CD45 is not due to a global change
in membrane structure, as the intensity of IgD, an isotype of BCR
that is expressed 10-fold higher than IgM9, was not increased
within the galectin-9 lattice (Supplementary Fig. 6a–c).
One of the best characterized inhibitory co-receptors expressed
on B cells is CD2242. The extracellular domain of CD22 is also
glycosylated and contains a sialic acid-binding domain, which
binds α2,6-linked sialic acids and mediates homotypic interac-
tions between CD22 molecules and heterotypic interactions with
other glycosylated proteins, including CD45 and IgM43,44. Thus,
we investigated if rGal9 also alters organization of CD22. We
observed clusters of CD22 with higher fluorescence intensity
inside the galectin-9 cap, which colocalized with IgM clusters
(Fig. 7e, f). Consistent with this, the mean fluorescence intensity
of CD22 is increased inside Gal9high regions (Fig. 7g). These
findings suggest that rGal9 increases the density of CD22,
coincident with the enrichment of IgM, within the galectin-9
lattice. Again, to confirm the specificity of CD22 enrichment
within the galectin-9 lattice, we examined localization of
inhibitory receptor FcγRIIb, upon treatment with rGal9, and
found no enrichment within Gal9high regions (Supplementary
Fig. 6d–f).
Our findings suggest that galectin-9 enhances the interaction
between IgM and CD22 and may provide a mechanistic basis for
a
b c
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Fig. 4 Galectin-9 binds IgM-BCR and CD45. a Schematic diagram of pull-down assay using FLAG-tagged rGal9 coupled to magnetic beads. Galectin-9-
interacting ligands were eluted by treatment with lactose and then identified by mass spectrometry. b Lactose eluted proteins from beads coated (+rGal9)
or not (−rGal9) with rGal9, or in the presence of lactose (+lac) or not (−lac) were subjected to SDS-PAGE following by immunoblotting using antibodies
specific to CD45 and IgM. c Cell lysates from primary murine B cells (lane 1), A20 B cells expressing Hel-specific IgM (D1.3; lane 2), A20 B cells (lane 3),
and Jurkat T cells (lane 4) were lysed and subjected to far-western analysis using FLAG-tagged rGal9. Reference blots probed for CD45 and IgM are shown
on the right. Data representative of three independent experiments
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the inhibitory effect of galectin-9 on B-cell activation. The
intracellular domain of CD22 contains three immunoreceptor
tyrosine-based inhibitory motifs that are phosphorylated upon
BCR ligation43 and recruit other phosphatases such as Src
homology region 2 domain-containing phosphatase-1 (SHP-1),
which dephosphorylates Syk, PLCγ2, and CD19 to dampen BCR
signaling45. Given our finding of reduced phosphorylation of
CD19 in BCR stimulated cells pre-treated with rGal9 (Fig. 3d), we
examined if CD19 is also localized within the galectin-9 lattice,
and found that CD19 is indeed enriched within Gal9high regions
(Fig. 7h–j). These findings suggest that galectin-9 reorganizes
IgM-BCR and its co-receptor CD19 together with inhibitory co-
receptors CD45 and CD22 to suppress BCR signaling.
GEMs (or lipid rafts) play an important role in initiation of
BCR signaling, and the localization of proteins within these
domains have important consequences for activation of signal-
ing46. We found that when B cells are treated with rGal9,
galectin-9 often forms a cap on one side of the cell, reminiscent of
the polarization of lipid rafts upon lymphocyte activation47,48.
Thus, we asked whether galectin-9 alters the distribution of lipid
rafts and association of CD45 and CD22 with these domains. We
treated primary B cells with rGal9 and then labeled lipid rafts
with fluorescently conjugated cholera toxin β-subunit (CT-B) and
immunostained for galectin-9, CD45, and CD22. Treatment with
rGal9 increased the intensity of CT-B within galectin-9 regions
and this region was enriched for CD45 and CD22 (Fig. 8a, b, e, f).
We generated masks defining CT-B-high (lipid raft high, LRhigh)
and CT-B-low (lipid raft-low regions, LRlow) regions and then
examined the intensity of CD45 and CD22 within these regions
(Fig. 8c). The mean intensity of both CD45 and CD22 is increased
within lipid raft-rich regions upon treatment with rGal9 (Fig. 8d,
g). Together with our previous findings, these data suggest that
treatment with rGal9 induces coalescence of lipid raft domains
containing CD45 and CD22 to suppress CD19 and BCR
activation.
Galectin-9 mediates association of IgM and CD22. We used
rGal9 as a tool to understand the molecular mechanism for
enhanced B-cell activation in galectin-9-deficient B cells. These
studies revealed that rGal9 alters the organization of CD45 and
CD22 with respect to IgM-BCR (Fig. 7) and this correlates with
suppressed BCR signaling (Fig. 3). To investigate if lack of
galectin-9 altered association of IgM-BCR with these proteins in
the steady state, we employed dual-color dSTORM to examine
colocalization of CD45 and CD22 with IgM-BCR in WT and
Gal9-KO B cells. We validated our dual-color dSTORM imaging
and analysis parameters by labeling IgM with both anti-IgM
coupled to Alexa 488 and Alexa 647 (Supplementary Fig. 7). We
labeled primary naive B cells from WT and Gal9-KO mice with
Alexa 488-labeled IgM-specific Fab fragment and Alexa 647-
labeled anti-CD45 (B220) or anti-CD22 and settled them on anti-
MHC II-coated coverslips. Dual-color dSTORM revealed that
CD45 is localized in nanoscale clusters, which minimally overlap
with IgM clusters in WT B cells, with no obvious difference
compared to Gal9-KO cells (Fig. 9a). We also found no difference
in the Hopkins index, H function curve, mean cluster diameter,
and mean cluster area of CD45 in WT and Gal9-KO B cells
(Fig. 9b–e). To examine colocalization of IgM and CD45 we
performed coordinate-based colocalization (CBC) analysis49,
which ranges from −1 (perfectly segregated) to +1 (perfectly
colocalized). CBC analysis of WT cells revealed a distribution
histogram with two peaks, one approaching −1 and one
approaching +1, indicating some degree of colocalization
between IgM and CD45 in the resting state; however, the median
CBC value for IgM and CD45 was 0.018 indicating that across the
population of molecules the distribution is largely uncorrelated
(Fig. 9f). We observed a similar distribution of correlation coef-
ficients and nearest-neighbor distance in Gal9-KO B cells (Fig. 9f,
g), suggesting that galectin-9 does not influence the association of
IgM and CD45 to a significant degree in the steady state.
In contrast to CD45, dual-color dSTORM of IgM and
CD22 showed a larger degree of colocalization based on visual
inspection of dSTORM images (Fig. 9h). Consistent with previous
reports50 CD22 is highly clustered on the surface of resting
primary naive B cells. We noted a small but statistically
insignificant difference in both the mean Hopkin’s index and
the H function curve, with CD22 appearing slightly less clustered
in Gal9-KO B cells compared to WT cells (Fig. 9i, j). However, we
noted no difference in mean cluster diameter or cluster area of
CD22 between WT and Gal9-KO B cells (Fig. 9k, l). CBC analysis
of colocalization of IgM and CD22 revealed that the frequency
distribution was right shifted in WT B cells, indicating that CD22
is more colocalized with IgM than CD45 in the steady state
(Fig. 9m). Indeed, the median CBC value in WT cells was 0.22. In
contrast, the median CBC value in Gal9-KO B cells was 0.12, and
the nearest-neighbor analysis revealed that the mean distance
between IgM and CD22 molecules was increased (Fig. 9m, n).
Table 1 Summary table of top hits of galectin-9-binding proteins identified by MS
UniprotKB ID Gene Log(e) Log(l) % Measured % Corrected Unique
peptides
Total
peptides
Mr Total peptides/
molecular weight
Q8VDN2 Atp1a1 −165.4 5.7 17 31 12 29 112.9 0.256864482
Q8C129 Lnpep −119.5 5.58 11 23 10 21 117.2 0.179180887
P06800 Ptprc −114.7 5.72 9.2 17 11 25 144.5 0.173010381
P24668 M6pr −75.3 5.8 21 36 5 16 31.2 0.512820513
Q03265 Atp5a1 −70.2 5.33 18 24 7 12 59.7 0.201005025
P11835 Itgb2 −63.2 4.98 6.8 9 4 7 84.8 0.08254717
P19437 Ms4a1 −60.9 5.71 22 60 5 25 31.9 0.78369906
P10852 Slc3a2 −59.2 5.34 13 21 5 12 62.2 0.192926045
Q8BG07 Pld4 −52.3 5.3 16 32 5 11 56.1 0.196078431
P01872 Ighm −39.3 5.3 8.6 16 3 9 50 0.18
Q62192 Cd180 −36.1 5.19 6.7 14 4 9 74.3 0.121130552
P51881 Slc25a5 −32.7 5.77 7 10 3 8 32.9 0.243161094
Q61735 Cd47 −25.6 5.39 7.7 26 2 11 35.3 0.311614731
P15530 Cd79b −18.8 5.11 7.6 22 2 7 32.1 0.218068536
O35424 H2-Ob −15.4 5.18 6.6 10 2 6 30.4 0.197368421
Relevant statistics from one replicate experiment. Top hits here identified using the following criteria: log(e) score≤−10; total peptides≥ 5; unique peptides≥ 2 in at least two independent experiments.
Hits observed in “no bait” controls were removed. Data acquired with input of 2e7 cells and 200mM lactose elution
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These findings suggest that galectin-9 mediates close association
between IgM and CD22, at least to some extent, in the
steady state.
Discussion
Here we identify galectin-9 as a negative regulator of B-cell
activation. We found that BCR microcluster formation and sig-
naling are enhanced in galectin-9-deficient B cells. Importantly,
we show that the ligands of galectin-9 at the cell surface are not
saturated in freshly isolated naive B cells and treatment with
rGal9 nearly abolishes BCR signaling. Using a pull-down assay
and mass spectrometry we identified IgM and CD45 as ligands of
galectin-9 in primary B cells. We further show that galectin-9
plays a role in regulating the spatial organization and dynamics of
IgM-BCR and its localization with regulatory surface proteins.
We propose that galectin-9 organizes IgM-BCR into larger clus-
ters that restrict the mobility of IgM and relocalizes inhibitory
molecules, including CD45 and CD22 to directly inhibit BCR
signaling (Fig. 10).
The spatial organization of cell surface proteins in constitutive
nanoscale clusters has emerged as a general principle of cell
surface proteins51. However, the molecular mechanism regulating
the size, composition, and stability of these assemblies is an open
question. The formation and stability of IgM-BCR nanoclusters is
not dependent on the actin cortex, as depolymerization of actin
does not alter the size or density of IgM-BCR nanoclusters9.
Thus, we hypothesized that the galectin-9 lattice may play a role
in the nanoscale organization of IgM-BCR. In contrast, super-
resolution dSTORM revealed no difference in the size or density
of IgM-BCR nanoclusters in galectin-9-deficient B cells. This is
consistent with a recent study demonstrating that glycan-based
interactions do not mediate the nanoclustering of dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-
integrin52. It may be that formation of BCR nanoclusters (or
oligomers) is largely dependent on the direct interaction of BCR
components, as suggested by Reth and colleagues16,53. However,
we do find that addition of rGal9 induces significant changes in
IgM-BCR organization. Inside the galectin-9 lattice, the number
of IgM-BCR nanoclusters decreased while the radius of clusters,
and the number of molecules in each cluster, increased. Thus, we
propose that galectin-9 provides a second layer of organization to
IgM-BCR by merging pre-existing nanoclusters.
But how does this observation square with our finding that
rGal9 suppresses BCR signaling? Indeed, these observations are
somewhat counter-intuitive given that BCR stimulation induces
the coalescence of BCR nanoclusters to form larger-scale signal-
ing microclusters9. So, how does the larger cluster of IgM induced
by galectin-9 not activate B cells, but instead inhibit BCR sig-
naling? We propose two potential mechanisms for galectin-9-
mediated control of BCR signaling. First, we propose that
galectin-9 induced merging of pre-existing nanoclusters decreases
Fig. 6 Galectin-9 immobilizes IgM-BCR and attenuates BCR
microclustering. a Diffusion coefficients and b frequency distribution
histogram of single-particle tracking of IgM in WT (black circle) or Gal9-KO
(blue diamond) primary B cells with the median indicated in red. Five
hundred representative diffusion coefficients from a total of at least 1500
tracks from three independent experiments. c Representative TIRF image of
fluorescently labeled rGal9 on primary B cell (left) and mask (right) created
to differentiate tracks inside Gal9 regions (lower left, red lines) and tracks
outside Gal9 regions (lower right, yellow lines). d Diffusion coefficients and
e frequency distribution inside Gal9 regions (black circle) and outside Gal9
regions (black triangle) with the median indicated in red. In all, 250
representative diffusion coefficients from a total of at least 900 tracks from
three independent experiments. f Representative TIRF microscopy images
of WT cell (top) and WT cells treated with 1 μM rGal9 (bottom) on artificial
planar lipid bilayers containing anti-kappa mapped to an 8-bit fire color
scale (ImageJ). g Quantification of the total antigen intensity at the cell-
bilayer interface in WT (black circles) and WT treated with rGal9 (open
circles), with the mean ± SEM indicated by the red bar. Scale bar represents
2 μm. Statistical significance assessed by Mann-Whitney; ****p <
0.0001, ***p < 0.001, **p < 0.01
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the lateral diffusion of IgM-BCR and consequently suppresses
BCR signaling. The mobility of IgM-BCR on the cell membrane
can be described as Brownian motion restricted by the underlying
actin cytoskeleton12,54. The theory of Brownian motion postulates
that the larger the particle the slower the movement of the par-
ticle55. Thus, we would predict that larger clusters of IgM-BCR
inside the galectin-9 lattice have a lower diffusion coefficient
compared to smaller clusters outside the galectin-9 lattice, con-
sistent with our data. This interpretation is supported by the
finding that in CD45-deficient B cells, homotypic clustering of
CD22 is enhanced, which correlates with decreased lateral dif-
fusion50. In addition, IgD-BCR is more densely clustered than
IgM-BCR9 and this correlates with a 10-fold lower diffusion
coefficient compared to IgM-BCR12. Thus, we propose that
galectin-9 restricts IgM-BCR mobility by organizing IgM-BCR
into larger clusters. The mobility of BCR on the cell surface is
correlated with BCR signaling; simply depolymerizing actin
increases BCR mobility and triggers spontaneous signaling12.
Consistent with this, treating B cells with lipopolysaccharide
increases actin severing and BCR mobility, which lowers the
threshold for B-cell activation54. Increased diffusion of the BCR
(or BCR nanoclusters) may be important for BCRs to join newly
forming microclusters. In agreement with this, treatment with
rGal9 decreased BCR microcluster formation upon stimulation by
membrane-bound antigen. Conversely, increased BCR diffusion
would be associated with more microclusters, in line with our
a
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observation of increased BCR mobility in galectin-9-deficient B
cells and enhanced B-cell activation.
Additionally, we propose that galectin-9 induced merging of
BCR nanoclusters regulates the interaction between IgM and the
co-receptors CD45 and CD22 to suppress BCR signaling. Our
finding of CD45 enrichment in the galectin-9 lattice is consistent
with our identification of CD45 as a ligand of galectin-9. The
N-terminal of CD45 has multiple N-glycosylation sites, providing
potential binding sites for galectin family members. Indeed, in
T cells, CD45 was reported to bind to galectin-156–58 and
galectin-933. In addition, galectin-3 has been reported to bind to
CD45 on diffuse large B-cell lymphoma59. These findings suggest
that CD45 may be a promiscuous ligand of the galectin family,
although differential glycosylation of CD45 in different immune
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cell subsets may provide specificity for distinct galectin binding.
Nonetheless, the enrichment of CD45 together with IgM inside
the galectin-9 lattice is consistent with the inhibitory effect of
galectin-9 on BCR signaling. Previous studies suggest that BCR
activation is accompanied by the segregation of BCR and CD45 in
order to promote Igα–Igβ phosphorylation41,60, consistent with
the finding that CD45 is excluded from BCR microclusters2. Our
finding that addition of rGal9 induces co-patching of CD45 and
IgM and concomitant abrogation of BCR signaling is consistent
with this model.
We also observed the enrichment of CD22 inside the galectin-9
lattice. CD22 is a known negative regulator of BCR signaling,
which recruits the phosphatase SHP-145, which dephosphorylates
CD1961 terminating the amplification of BCR signaling. In
addition, SHP-1 dephosphorylates PLCγ2 and attenuates MAPK
activation42. Thus, the localization of CD22 together with IgM-
BCR upon rGal9 treatment is consistent with our observation of
reduced phosphorylation of CD19 and ERK1/2 and likely con-
tributes to the inhibitory effect of galectin-9 on B-cell activation.
Moreover, in resting naive B cells, dual-color dSTORM
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Fig. 10 Schematic model of galectin-9 regulation of B-cell activation. a In resting primary naive WT B cells, galectin-9 facilitates interactions between BCRs
and either the inhibitory proteins CD45 or CD22 through binding to N-linked glycans, providing a basal attenuation of B-cell signaling upon antigen
stimulation. b BCR signaling is enhanced in Gal9-KO B cells due to loss of association of BCR with inhibitory co-receptors. c Treatment of WT B cells with
rGal9 induces the association of IgM-BCR with CD45 and CD22 to suppress B-cell signaling
Fig. 9 Galectin-9 increases colocalization between CD22 and IgM in primary B cells. a Representative merged TIRF (top), dSTORM (middle), and dSTORM
zoom (bottom) images showing surface CD45 (magenta) and IgM-BCR (green) on primary wild-type (WT) (left) and galectin-9 knockout (Gal9-KO)
(right) B cells. dSTORM ROI (3 × 3 μm) is outlined in yellow (middle) and magnified in dSTORM zoom (bottom). b–e Quantification of at least 20 ROIs
from WT and Gal9-KO B cells pooled from three independent experiments. b Hopkin’s index showing randomness of CD45 organization (one point
per ROI). c H function derived from Riplely’s K showing degree of CD45 clustering. d Mean diameter of CD45 clusters (one point per ROI). e Mean
area of CD45 clusters (one point per ROI). f, g Quantification of at least 15 ROIs from WT and Gal9-KO B cells pooled from three independent
experiments. f Coordinate-based colocalization (CBC) histograms of the single-molecule distributions of colocalizations between CD45 and IgM.
g Nearest-neighbor distance (NND) analysis of the data shown in f. Symbol represents the median NND of all paired single-molecule localizations from
one ROI. h Representative merged TIRF and dSTORM images showing surface CD22 (magenta) and IgM-BCR (green) on primary WT (left) and Gal9-KO
(right) B cells. i–l Quantification of at least 30 ROIs from WT and Gal9-KO B cells pooled from three independent experiments. i Mean Hopkin’s index
showing randomness of CD22 organization (one point per ROI). j H function showing degree of CD22 clustering. k Mean diameter of CD22 clusters (one
point per ROI). l Mean area of CD22 clusters (one point per ROI). m, n Quantification of at least 20 ROIs from WT and Gal9-KO B cells pooled from three
independent experiments. m CBC histograms of the single-molecule distributions of colocalizations between CD22 and IgM. n NND analysis of the data
shown in m. Colocalization between channels shown in white. Scale bars represent 2 and 1 μm (zoom). Mean ± SEM indicated by the red bar. Statistical
significance assessed by Mann-Whitney, *p < 0.05
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demonstrated that the colocalization of IgM and CD22 is reduced
in galectin-9-deficient B cells, providing a plausible mechanism
for enhanced BCR signaling in Gal9-KO B cells.
Interestingly, we found that the ligands for galectin-9 are not
saturated in naive B cells and raises the possibility that BCR
signaling could be modified under conditions that affect the
secretion of galection-9. It is currently not known if B cells secrete
galectin-9, which binds to the cell surface, or if other cells
secrete galectin-9, which then binds to the surface of B cells.
Indeed, galectin-9 is expressed in multiple cell types, including
T cells, natural killer cells, and monocytes62. Alterations in
galectin-9 secretion and its association with cell surface proteins
would provide a mechanism to adjust the threshold of B-cell
activation and thus tune B-cell responses. Moreover, recent
reports indicate that galectin-9 is induced under inflammatory
conditions in peripheral blood mononuclear cells and mesench-
ymal stromal cells63, and elevated in the serum of patients in a
variety of infections, including HIV, cytomegalovirus, and dengue
infection64–66. How this affects the B-cell response in these
infections is an important question to address.
Methods
Mice. C57BL/6 (WT) mice were obtained from Charles River, Lgals9−/− (Gal9-
KO) mice were obtained from Steven Beverley (Washington University) on behalf
of The Scripps Research Institute, and Lgals1−/− (Gal1-KO) were obtained from
The Jackson Laboratory. Mice were used at 2–6 months of age for all functional
and biochemical experiments and were age- and sex-matched within each
experiment. Mice were housed in specific pathogen-free animal facility at Uni-
versity of Toronto Scarborough, Toronto, Canada. All procedures were approved
by the Local Animal Care Committee at the University of Toronto Scarborough.
Cell lines and culturing. A20 B cells and A20 expressing Hel-specific IgM (D1.3)
were obtained from F. Batista (Ragon Institute), and Jurkat T cells were obtained
from T. Watts (University of Toronto). Cell lines were not tested for mycoplasma
contamination. Cells were maintained at 37 °C with 5% CO2 in RPMI 1640 con-
taining 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin and
streptomycin (all from Gibco), and 50 µM 2-mercaptoethanol (Amresco).
Cell isolation. Splenocytes were isolated from C57BL/6 WT, Gal9-KO, and Gal1-
KO mice using 70 µm cell strainer and phosphate-buffered saline (PBS, pH 7.4, Life
Technologies) to collect a single-cell suspension. B cells were purified using
negative isolation kit (Miltenyi Biotec Inc. or Stem Cell technologies) according to
the manufacturer’s protocol.
Immunohistochemistry. Inguinal lymph nodes from C57BL/6 mice were isolated
and immersed in Optimal Cutting Temperature compound (TissueTek) followed
by submersion in 2-methylbutane cooled in liquid nitrogen. Frozen tissue blocks
were cryosectioned into 12 μm slices and adhered to Superfrost Plus microscope
slides (VWR), fixed in 4% paraformaldehyde (PFA), and then air-dried. Tissue
slices were rehydrated with PBS for 15 min, permeabilized with 0.5% Tween-20 in
PBS for 5 min, then blocked with 5% goat serum in PBS for 30 min. Sections were
incubated with CD169-FITC (clone 3D6.112, Biolegend), B220-allophycocyanin
(APC) (clone RA3-6B2, Invitrogen), and goat anti-mouse galectin-9 (R&D Sys-
tems, Cat. No. AF3535) at 1:200 v/v in blocking buffer for 1 h at room temperature.
Sections were washed five times with 0.5% Tween-20 in PBS, and then incubated
with secondary antibody Cy3-conjugated bovine anti-goat (Jackson Immunor-
esearch, Cat. No. 805-165-180) at 1:1000 v/v for 1 h at room temperature. Slides
were washed five times and then mounted in Fluoro-Gel with DABCO™ Anti-
fading Mounting Medium. Slides were imaged by laser scanning confocal micro-
scopy with Zeiss LSM510 Meta using a ×100/numerical aperture (NA) 1.40 oil-
immersion objective.
Surface staining of galectin-9 for flow cytometry and imaging. C57BL/6, Gal9-
KO, or rGal9-treated B cells were first blocked with purified rat anti-mouse CD16/
32 (Fc-block, 1:250 v/v, clone FCR-4G8, Invitrogen) in fluorescence-activated cell
sorting (FACS) buffer (1% bovine serum albumin (BSA), 4 mM EDTA, and 0.01%
NaN3 in PBS) for 30 min at 4 °C. Cells were washed three times with FACS buffer
and then immunostained with phycoerythrin-conjugated rat anti-mouse galectin-9
antibody (clone 108A2, Biolegend) at 1:200 v/v, or stained with goat anti-galectin-9
antibody (R&D Systems, Cat. No. AF3535) at 1:100 v/v in FACS buffer for 30 min
at 4 °C, followed by Cy3-conjugated AffiniPure bovine anti-goat antibody (Jackson
ImmunoResearch Laboratories, Cat. No. 805-165-180) at 1:1000 v/v in FACS buffer
for 30 min at 4 °C. Cells were then stained with the following antibodies: APC-
conjugated anti-CD19 (clone ID3, Biolegend) at 1:200 v/v; Alexa Fluor 488 or
Alexa Fluor 644 AffiniPure Fab fragment rat anti-mouse IgM, μ-chain-specific
(Jackson ImmunoResearch Laboratories, Cat. No 115-547-020 or Cat. No 115-607-
020) at 1:200 v/v in FACS buffer for 30 min at 4 °C. Cells were washed and
resuspended in FACS buffer for flow analysis or imaged by spinning disc confocal
microscopy. Cells were analyzed by flow cytometry (BD Fortessa) and plotted using
Flowjo software (TreeStar). Cells were imaged by spinning disc confocal micro-
scopy (Quorum Technologies) consisting of an inverted fluorescence microscope
(DMI6000B; Leica) equipped with a ×63/1.4 NA oil-immersion objective and an
electron-multiplying charge-coupled device (EMCCD) camera (ImagEM; Hama-
matsu). Fluorescence intensity images of galectin-9 were pseudo-colored using the
fire lookup table in ImageJ. Quantification of number of puncta for all z-sections
was performed in ImageJ using a threshold of 2× background intensity followed by
“Analyze Particles” algorithm with the following parameters: size 5–100; circularity
0.00–1.00.
Planar lipid bilayer. Artificial planar lipid bilayers were prepared by liposome
spreading67 in FCS2 chambers (Bioptechs). 1, 2-dioleoyl-sn-glycero-3-phospho-
coline liposomes (Avanti Polar Lipids, Inc.) were mixed with 2.5 × 10−4% bioti-
nylated (N-Biotinyl Cap PE; Avanti Polar Lipids, Inc) liposomes. Alexa Fluor 633-
streptavidin (1:1000 v/v Life Technologies, Cat. No S21375) was used to tether
monobiotinylated anti-mouse kappa light chain (clone HB58, purified in house
from hybridoma) as surrogate antigen. Cells were assayed in chamber buffer (0.5%
FBS, 2 mM MgCl2, 0.5 mM CaCl2, and 1 g/L D-glucose in PBS). Freshly isolated
splenocytes from WT and Gal9-KO mice were allowed to spread and form clusters
for 90 s, and then fixed with 4% PFA for 15 min at 37 °C. Cells were imaged using a
spinning disc confocal microscope as described above. Images were analyzed using
Volocity (Perkin Elmer) to quantify area of cell-bilayer contact, total antigen
intensity, and mean antigen intensity, and plotted using Prism6 (GraphPad).
Antigen was pseudo-colored using the fire lookup table provided in ImageJ
(National Institutes of Health).
Pull-down assay and mass spectrometry. The protocol was adapted from ref. 33.
In all, 107–5 × 107 purified B cells from Gal9-KO mice were lysed in NP40 lysis
buffer (50 mM HEPES (pH 8.0), 150 mM NaCl, 5 mM dithiothreitol (DTT), 5 mM
EDTA, 0.1 % Nonidet-P40, and Roche cOmplete mini EDTA-free protease inhi-
bitor) with three cycles of freeze/thaw using liquid nitrogen. Lysates were cleared
by centrifugation at 21 000 × g for 10 min at 4 °C. The cell lysate was incubated with
anti-FLAG beads (Sigma-Aldrich) conjugated with 10 µg FLAG-tagged rGal9
(kindly provided by M. Ostrowski, University of Toronto) for 3 h at 4 °C. Beads
were subjected to magnetic separation and washing in lysis buffer. Bound proteins
were first eluted by 200 mM lactose solution (in distilled water), followed by
denaturing elution (125 mM NH4OH). Denatured eluents were evaporated to
dryness to remove NH4OH using a vacuum centrifuge, followed by resuspension in
50 mM ammonium bicarbonate (pH 8.0). Both eluents were then subjected to in-
solution tryptic digestion followed by peptide desalting and concentration using
OMIX C18 tips (Agilent) according to the manufacturer’s instructions. Eluted
peptides were dried by vacuum centrifugation and stored at −20 °C prior to
analysis. Peptide separations were performed with an increasing acetonitrile gra-
dient (5–40% acetonitrile and 0.1% formic acid) over 90 min using an EASY nLC-
1000 HPLC equipped with a 10.5 cm C18 column coupled online to an LTQ XL
mass spectrometer (Thermo). MS1 scans were acquired between 400 and 1800m/z,
and up to six of the most intense parent ions were selected for collision-induced
dissociation with an isolation width of 2 Da and normalized collision energy of 35
eV. Parent ions selected for analysis more than three times in 30 s were dynamically
excluded from analysis for 45 s. Raw spectra were converted to mzXML format
using msConvert (PMID: 23051804) and searched against the mouse and Escher-
ichia coli proteomes as well as the sequence of Lgals9 and a database of commonly
observed contaminants using X! Tandem (PMID: 14976030). Parent ion tolerances
were set to +3 and −2 Da and fragment ion mass tolerance was set to 0.4 Da.
Oxidation of methionine and tryptophan, as well as deamidation of asparagine and
glutamine was permitted as potential modifications during refinement. Results
were further compared using ProhitsVM68.
Pull-down assay for western blotting. A total of 1–3 × 107 purified B cells from
Gal9-KO mice were lysed in RIPA buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA,
1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, and 1 mM
phenylmethylsulfonyl fluoride (PMSF)). Lysates were cleared by centrifugation at
21 000 × g for 10 min at 4 °C. Cell lysates were incubated with anti-FLAG beads
(Sigma-Aldrich) conjugated with 10 µg FLAG-tagged rGal9 for 3 h at 4 °C in the
presence or absence of 50 mM D-lactose. Beads were subjected to magnetic
separation and washed in RIPA buffer. Bound proteins were eluted using 200 mM
D-lactose in PBS. Protein was mixed with equal volume of 2× Laemmli sample
buffer, heated to 95 °C for 10 min, and separated by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE). Proteins were transferred to polyvinylidene fluoride
(PVDF) membrane and blocked with 5% non-fat milk in TBST (20 nM Tris
(pH 7.5), 150 mM NaCl, and 0.1% Tween-20) for 30 min at room temperature with
gentle shaking. Primary antibodies rat anti-mouse CD45RA (clone 30-F11; Bio-
Legend) and goat anti-mouse IgM (Jackson Immunoresearch, Cat. No. 115-005-
020) were incubated at 1:1000 overnight at 4 °C with gentle shaking. Secondary
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antibodies horseradish peroxidase (HRP)-conjugated donkey anti-rat and donkey
anti-goat (Abcam, Cat. No ab102182 and ab97110) were incubated at 1:10 000 in
5% non-fat milk in TBST for 1 h at room temperature with gentle shaking.
Membranes were washed with TBST and developed with chemiluminescent sub-
strate (West Pico, Thermo Fisher), and imaged by ChemiDoc (Bio-Rad).
Far-western blotting. In all, 1–5 × 107 purified primary murine B cells, D1.3 B
cells, A20 B cells, or Jurkat T cells were lysed in RIPA buffer (10 mM Tris-HCl pH
8.0; 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM
NaCl, and 1 mM PMSF). Lysates were cleared by centrifugation at 21 000 × g for
10 min at 4 °C. A unit of 25 µg of whole-cell lysate was resolved by 10% SDS-PAGE
and transferred to PVDF membrane. Proteins were re-natured in decreasing
concentrations of guanidine-HCl (6–0M) according to ref. 34. Membranes were
then blocked with 5% non-fat milk in TBST for 30 min at room temperature with
gentle shaking. A unit of 5 µg/mL FLAG-tagged-recombinant galectin-9 in 2.5%
skim milk in TBST was used as a bait protein, blots were incubated with bait
protein overnight at 4 °C with gentle shaking. Blots were then washed and incu-
bated with anti-FLAG (clone M2, Sigma-Aldrich) at 1:1000 in 5% skim milk in
TBST for 1 h at room temperature. Blots were washed and incubated with HRP-
conjugated anti-mouse antibody (Jackson Immunoresearch, Cat. No. 115-035-003)
at 1:10 000 in 5% non-fat milk in TBST for 1 h at room temperature with gentle
shaking. Membranes developed with chemiluminescent substrate (West Pico,
Thermo Fisher) and imaged by ChemiDoc (Bio-Rad).
rGal9 and Fab fragment labeling for single-particle tracking. Mouse rGal9
(R&D Systems) was reconstituted at 0.2 mg/mL in 0.1 M NaHCO3 and incubated
with 0.2 mg/mL Alexa Fluor® 555 NHS Ester for 1 h at room temperature with
gentle mixing. Following labeling, the mixture was dialyzed against 20 mM MOPS,
500 mM sodium chloride, 0.5 mM EDTA, and 1 mM DTT using a 10 000 mole-
cular weight cutoff Slide-A-Lyzer® Dialysis Cassette (Thermo Scientific). A volume
of 20 µl of 1 M NaHCO3 was added to 200 µl of 1 mg/mL goat anti-mouse IgM, µ-
chain-specific (Jackson ImmunoResearch, Cat. No. 115-007-020) and incubated
with 40 µg/mL Attotec® 633 NHS Ester for 1 h at room temperature with gentle
mixing. Following labeling, the mixture was dialyzed against PBS.
Glass coverslip coating for single-particle tracking. Glass coverslips were
cleaned in chromic acid (Fisher) for 20 min followed by rinsing with water and
acetone. Coverslips were air-dried and then incubated with 1 µg/mL anti-MHC
class II (clone M5/114, Sunnybrook Research Institute) for 2 h at room tempera-
ture and then washed with PBS.
Cell labeling for single-particle tracking. Primary murine B cells from WT and
Gal9-KO mice were labeled with 4 ng/mL Attotec® 633-labeled goat anti-mouse
IgM Fab fragment (Jackson ImmunoResearch, Cat. No. 115-007-020) in 0.5% FBS
in PBS for 15 min at 4 °C. For rGal9 treatment, 5 × 106 B cells from Gal9-KO mice
were incubated with 0.5 µM labeled rGal9 mixed with 0.5 µM non-labeled rGal9 in
complete media for 30 min at 37 °C. Labeled cells were washed twice with PBS and
resuspended in chamber buffer. Labeled cells were stored on ice prior to imaging.
Just before imaging, cells were incubated at 37 °C for 5 min.
Instrument for single-particle tracking and dSTORM. Single-molecule fluores-
cence microscopy was performed with a TIRF microscope (Quorum Technologies)
based on an inverted microscope (DMI6000B; Leica), HCX PL APO ×100/1.47 oil-
immersion objective, and Evolve Delta EMCCD camera (Photometrics). Images
were acquired continuously at 20 frames/s for 10 s with an EM gain of 200 and the
exposure time of 50 ms.
Single-particle tracking. We used the well-established single-particle tracking
algorithm by Crocker and Grier69 implemented in Matlab (The MathWorks) by
Daniel Blair and Eric Dufresne (http://physics.georgetown.edu/matlab/). Particle
positions were determined by measuring the the centroid position with sub-pixel
accuracy based on the local maxima and then linking particle positions. Track
lengths < 10 were discarded in order to reduce statistical noise. Diffusion coeffi-
cients for individual trajectories were determined form the first three data points of
the mean squared displacement curves of each trajectory.
Sample preparation for dSTORM. Primary B cells from WT and Gal9-KO mice
were stained with Alexa Fluor 647-conjugated Fab fragment goat anti-mouse IgM,
µ-chain-specific (Jackson ImmunoResearch, Cat. No. 115-607-020) at 1.5 µg/mL in
PBS containing 2% FBS for 15 min at 4 °C, then washed twice with PBS. For dual-
color dSTORM, primary WT and Gal9-KO B cells were stained with Alexa Fluor
488-conjugated Fab fragment goat anti-mouse IgM, µ-chain-specific (Jackson
ImmunoResearch, Cat. No 115-547-020) at 2.8 µg/mL and either Alexa Fluor 647
anti-mouse CD22 (OX-97, Biolegend) at 2.5 µg/mL or Alexa Fluor 647 anti-mouse/
human B220 (RA3-6B2, Biolegend) at 2.5 µg/mL all in PBS containing 2% FBS for
20 min at 4 °C, then washed twice with PBS. Cells were allowed to spread on anti-
MHC-class II-coated coverslips for 10 min at 37 °C. Coverslips were washed gently
with PBS to remove unbound cells. Cells were fixed with fixation solution (4% PFA
and 0.2% glutaraldehyde in PBS) for 40 min at room temperature. The coverslips
were washed three times with PBS. Before single-color dSTORM imaging, samples
were incubated in PBS containing 0.1 M mercaptoethylamine, 0.5 mg/mL glucose
oxidase, 40 μg/mL catalase, and 10% glucose. For dual-color dSTORM, samples
were incubated in PBS containing 0.1 M β-mercaptoethylamine hydrochloride
(Sigma-Aldrich), 3% (v/v) OxyFlour™ (Oxyrase Inc., Mansfield, Ohio, USA), 20%
(v/v) of sodium DL-lactate solution (L1375, Sigma-Aldrich) adjusted to pH ~ 8.3.
Fiducial markers (100 nm TetraSpeck Fluorescent Microspheres, Invitrogen) were
added to buffer and allowed to settle for 5 min prior to imaging.
dSTORM acquisition and image reconstruction. dSTORM images were acquired
on a TIRF microscope as described above. For Alexa Fluor® 647, photoconversion
was achieved with 633-nm laser (intensity ranged from 80 to 100 mW/cm2) illu-
mination and conversion from the dark state with 488-nm laser illumination
(intensity range from 5 to 20 mW/cm2). Ten thousand images were acquired at a
frame rate of 33 frames/s. Dual-color dSTORM images were acquired sequentially
on a TIRF microscope, first imaging Alexa 647 followed by Alexa 488 to prevent
photobleaching of Alexa 647. For Alexa Fluor® 647, photoconversion was achieved
with 633-nm laser (intensity ranged from 80 to 100 mW/cm2) illumination and
conversion from the dark state with 402-nm laser illumination (intensity range
from 5 to 20 mW/cm2). For Alexa Fluor® 488, photoconversion was achieved with
488-nm laser (intensity ranged from 80 to 100 mW/cm2). Eight thousand images
were acquired at a frame rate of 30 frames/s. Fiducial markers, which were visible
in both the 488- and 647-nm channels, were used to align the two channels. The
images of the beads in both channels were used to calculate a polynomial trans-
formation function that mapped the 488-nm channel onto the 647-nm channel,
using the MultiStackReg plugin of ImageJ. The transformation matrix was applied
to each frame of the 488-nm channel stack. Reconstructed images were acquired
using ThunderSTORM plugin for ImageJ70 according to the parameters shown in
Supplementary Fig. 8A. Briefly, camera setup was as follows: pixel size (101.5 nm);
photoelectron per A/D count 2.4; base level [A/D count] 414; and an EM gain of 50
(dSTORM) or 200 (dual-color dSTORM). Image filtering was applied to remove
camera noise and enhance photoswitching events using a wavelet filter (B-Spline)
with B-Spline order of 3 and B-Spline scale of 2.0. Approximate localization of
molecules was detected by local maximum method with a peak intensity threshold
of std (Wave.F1) and a connectivity of 8-neighborhood. Sub-pixel localization of
molecules was identified by fitting point spread function to an integrated Gaussian
using weighted least squares method with a fitting radius of 3 pixels. Single
molecules may not be adequately resolved in spatially dense organizations and
thereby multiple activated molecules are detected as a single blob. Multiple emitter
fitting analysis was used to estimate the number of molecules detected as a single
blob with maximum five molecules per fitting region. To improve the multi-emitter
fitting algorithm, molecules are fitted assuming the same intensity. Super-
resolution images were rendered with a pixel size of 20 nm.
dSTORM post-processing, analysis, and quantification. Reconstructed
dSTORM images were post-processed with drift correction using the built-in
method in the ThunderSTORM plugin. The workflow for post-processing steps is
shown in Supplementary Fig. 8B and consisted of the following steps: (1) remove
duplicates, in which repeated localizations of single molecules in one frame, which
may occur when using multiple emitter, were removed based on uncertainty radius
of localization; (2) filter, in which localizations with an uncertainty >20 nm were
eliminated; (3) density filter, in which isolated localizations were removed based on
the parameter of at least two neighbors are required in 50 nm radius for a locali-
zation to be accepted; (4) drift correction, in which image drift was corrected using
fiducial markers; and (5) merging, in which molecules that appeared within 20 nm
in multiple frames were merged together. The number of localizations across cells
and conditions was similar (Supplementary Fig. 8C). Performance evaluation of
dSTORM analysis and post-processing parameters was performed (Supplementary
Methods; Supplementary Fig. 9). To reduce processing time, 4000 frames were
processed for cluster analysis. For each reconstructed image of WT and Gal9-KO B
cells, a 3 × 3 µm region was manually selected but excluded from the cell boundary.
For each reconstructed image of rGal9-treated Gal9-KO B cells, a 3 × 3 µm region
that colocalized with Gal9, was manually selected for analysis. The Hopkins index
and Ripley’s H function analysis were performed by SuperCluster, an analysis tool
kindly provided by the University of New Mexico’s Spatio Temporal Modeling
Center (http://stmc.unm.edu/). Cluster analysis was performed by a Bayesian, a
model-based approach38. In brief, uncertainty, x and y coordinates of each loca-
lization in post-processed reconstructed images were exported. The selected 3 × 3
µm regions were analyzed by the published R code of Bayesian cluster analysis38
with an alpha value of 20, pbackground of 0.5, rseq of (5, 200, 10), and thseq of (0,
50, 5). The analyzed data were post-processed to extract data about percentage of
molecules localizing in clusters, cluster radius, number of clusters, and number of
molecules per clusters.
CBC analysis. Colocalization of dual dSTORM data was conducted using CBC
analysis49 using ThunderSTORM. Briefly, this method uses coordinate information
of each molecule instead of an intensity-based approach, which would depend on
the reconstruction and post-processing parameters chosen. Furthermore, this
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method takes into account the spatial distribution of each set of localizations to
prevent false positive colocalization values that result when one of the molecular
species is randomly organized. First, the spatial distribution function of the
neighboring localizations from the same species in each channel are calculated.
Then, from the individual distribution functions, a correlation coefficient is cal-
culated and weighted by distance to the nearest neighbor of the localization’s
respective species. As a result, each single molecule of each species is attributed an
individual colocalization value, which provides information on the molecule’s local
environment. CBC algorithm was applied to x–y coordinate lists of localizations in
the 3 × 3 µm region of 647 and 488 channels. A search radius of 70 nm, based on
the radius IgM nanoclusters, was used to calculate degree of colocalization values
varying from −1 (perfectly excluded) to +1 (perfectly colocalized).
Cell stimulation for western blot. Twenty-four-well plates were coated with 5 µg/
mL AffiniPure F(ab′)2 fragment goat anti-mouse IgM, μ-chain-specific (Jackson
ImmunoResearch Laboratories, Cat. No 115-006-020) in PBS overnight at 4 °C.
Primary naive splenic B cells from WT and Gal9-KO mice were stimulated for the
indicated time, then lysed with Laemmli buffer containing 100 µM DTT followed
by SDS-PAGE. For rGal9 treatment, Gal9-KO or WT B cells were pre-treated with
0.1 or 1 µM, respectively, with recombinant mouse galectin-9 (rGal9, E. coli-
derived, R&D Systems) in RPMI containing 1% FBS (both Gibco) and incubated
for 30 min at 37 °C. Cells were then washed once with RPMI and then stimulated
as described above. Proteins were transferred to PVDF and blocked with 5% non-
fat skimmed milk or 5% BSA in TBST for 1 h at room temperature or overnight
(for 4G10) at 4 °C with shaking. Membranes were immunoblotted with the fol-
lowing antibodies overnight or for 3 h (for 4G10) at 4 °C: mouse anti-β-tubulin
(Sigma, 1:5000 in 1% BSA/TBST); rabbit anti-phospho-p44/42 MAPK (ERK1/2
Cell Signaling, Cat. No. 9101, 1:1000 in 1% BSA/TBST); rabbit anti-ERK p44/42
MAPK (ERK1⁄2 Cell Signaling, Cat. No. 9102); 4G10 (Sunnybrook Research
Institute, 1:1000 in 1% BSA/1% NaN3/TBST); phospho-CD19 (Tyr531 Cell Sig-
naling, Cat. No. 3571, 1:1000 in 1% BSA/1% NaN3/TBST); and phospho-Akt
(Tyr308 Cell Signaling, Cat. No. 4056, 1:1000 in 1% BSA/1% NaN3/TBST). HRP-
conjugated secondary antibodies were used at 1:10 000 v/v in 5% non-fat skimmed
milk in TBST or 1% BSA in TBST and incubated for 2 h with shaking at room
temperature. Membranes were incubated with SuperSignal (Thermo Fisher Sci-
entific) chemiluminescent substrate and then imaged by ChemiDoc (Bio-Rad).
Densitometric analysis of western blots was performed using ImageJ (NIH). The
amount of phosphorylated protein was normalized to loading control and then
expressed as a fold change relative to the 0 min time point. Full blots for all cropped
blots presented in the figures are shown in Supplementary Fig. 10.
Calcium signaling. Intracellular Ca2+ flux was measured by flow cytometry. Freshly
isolated splenocytes (5 × 106 cells/sample) were labeled with 1 μM Fluo-4, AM
(Thermo Fisher) in 10% FBS/Hank’s balanced salt solution at 37 °C for 15min. Cells
were incubated with anti-CD45R (B220) (clone RA3-6B2; Biolegend) for 5 min at
4 °C at a dilution of 1:200. Cells were washed 2× with PBS and resuspended in RPMI.
After collecting a baseline reading for 30 s, 20 μg/mL anti-mouse kappa immu-
noglobulin light chain (clone HB58) or 1 μM rGal9 was added to the facs tube, and
change in fluorescence intensity was recorded on a Fortessa cytometer (BD Bios-
ciences) and plotted using Flowjo software (TreeStar). Fold change was calculated by
dividing the fluorescence intensity at each time point by baseline intensity.
rGal9 treatment and confocal imaging. Eight-well Lab-Tek chambers were
coated with 1 µg/mL anti-mouse MHC II (M5/114, Sunnybrook Research Institute)
antibody in PBS for 2 h at room temperature. In all, 5 × 106 primary murine B cells
from WT mice were treated with 1 µM recombinant galectin-9 in 2% FBS in RPMI
for 30 min at 37 °C. Cells were washed 1× with PBS. Cells were resuspended in PBS
and allowed to adhere to chambers for 15 min. Cells were fixed in 2% PFA for
10 min and then washed 2× in FACS buffer (PBS, 1% BSA, and 0.1% NaN3). Cells
were incubated with 2 µg/mL purified rat anti-mouse CD16/32 (clone 2.4G2,
BDPharmingen) in PBS for 15 min at 4 °C. Cells were incubated with 1 µg/mL goat
anti-mouse Gal9 (R&D systems, Cat. No. AF3535) in FACS buffer for 1 h at 4 °C.
Cells were washed 3× with FACS buffer. If cells were stained to visualize CD16/32,
cells were incubated with 1 µg/mL Alexa-Fluor594 Donkey Anti-Rat IgG (Invi-
trogen Cat. No A-21209) for 1 h at 4 °C. Cells were washed 2× with PBS. Cells were
incubated with 1 µg/mL Cy3-conjugated bovine anti-goat IgG (Jackson Immu-
noResearch, Cat. No. 805-165-180) or Alexa Fluor 488 donkey anti-goat IgG
secondary (Jackson ImmunoResearch, Cat. No. 705-545-147) for 1 h at 4 °C. Cells
were washed 3× with PBS. Cells were stained with fluorochrome-conjugated
antibodies specific for CD45/B220 (RA3-6B2, BD Biosciences), CD22 (OX-97,
Biolegend), CD19 (1D3, Biolegend), IgD (11-26c.2a, Biolegend) at 1:100 v/v or IgM
(Jackson ImmunoResearch) at 1:1000 v/v for 1 h at 4 °C. Cells were washed 3× with
PBS. Cells were mounted in Fluoro-Gel with DABCOTM (Electron Microscopy).
Chambers were imaged by spinning disk confocal microscopy (Quorum Tech-
nologies) consisting of an inverted fluorescence microscope (DMI6000B; Leica)
equipped with a ×63/1.4 NA oil-immersion objective and an EMCCD camera
(Image EM; Hamamatsu). Images were acquired using Metamorph software
(Molecular Devices). Images were analyzed using Volocity software (Perkin Elmer).
The fluorescence signal of CD45, CD22, CD19, IgM, IgD, or FcγRIIb was used to
define a mask delineating the membrane region. Gal9high regions were determined
by the fluorescence signal of Gal9. Gal9low regions were determined by subtracting
the Gal9high regions from the membrane region. The mean florescence intensity of
CD45, CD22, CD19, IgD, FcγRIIb, and IgM was calculated in Volocity.
Lipid raft staining. Primary murine WT B cells and 1 µM rGal9-treated B cells
were labeled with 1 µg/mL Alexa Fluor 555-conjugated Cholera toxin subunit B
(Vybrant™ Alexa Fluor™ 555 Lipid Raft Labeling Kit, Thermo Fisher Scientific) for
15 min on ice. Cells were washed 2× with PBS for 5 min at 4 °C. Cells were then
allowed to adhere to anti-MHC II-coated Mattek chambers for 10 min. Cells were
fixed with 2% PFA for 15 min and washed 3× with PBS. Cells were then stained for
specific proteins as described above.
B-cell apoptosis. Freshly isolated naive B cells from WT and Gal9-KO mice were
treated with 1 μM recombinant mouse galectin-9 (rGal9, E. coli-derived, R&D
Systems) for 30 min at 37 °C, followed by staining with Fluorescein isothiocyanate
(FITC)-conjugated Annexin V and propidium iodide according to the manu-
facturer’s protocol (Annexin V Apoptosis Detection Kit, eBioscience), and analyzed
by flow cytometry (BD Fortessa). Data were analyzed using FlowJo software.
Statistical analysis. Statistical analysis was performed using GraphPad Prism. The
distribution of data was tested using D’Agostino-Pearson omnibus normality test.
Comparisons between two groups were performed using Mann-Whitney for data
with non-normal distribution. Comparisons between multiple groups were per-
formed by ordinary one-way analysis of variance (ANOVA) for data with normal
distribution and Kruskal-Wallis test for data with non-normal distribution. For
post hoc analysis, Tukey’s multiple comparison was used for normally distributed
data and Dunn’s multiple comparisons test was used for non-normally distributed
data. Western blot data were analyzed by two-way ANOVA followed by Sidak’s
multiple comparisons test. Sample sizes were chosen based on prior literature using
similar methods and reporting moderate effect size. Estimate of variance is
reported as standard error of the mean for each data set.
Code availability. ThunderStorm plugin for ImageJ is available at http://zitmen.
github.io/thunderstorm/. SuperCluster is available from the University of New
Mexico’s Spatio Temporal Modeling Center (http://stmc.unm.edu/). Bayesian
cluster analysis code is available in supplementary information in ref. 38. Single-
particle tracking algorithms implemented in Matlab (The MathWorks) is available
at http://physics.georgetown.edu/matlab/.
Data availability. Lgals9−/− mice require an MTA from The Scripps Research
Institute (TSRI). The data that support the findings of this study are available from
the corresponding author upon reasonable request.
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